# JAPFA Distribution Agreement Review — Syria · Levant Animal Health (Al Haytham) **Advisory analysis only. Not a substitute for licensed Indonesian legal counsel — review with internal legal before signing.** --- ## Cover Block | Field | Value | |---|---| | Counterparty (per recital) | **AL HAYTHAM FOR TRADE LIMITED LIABILITY COMPANY (LEVANT ANIMAL HEALTH)** — a single Syrian LLC trading under two names | | Registered office | Damascus, Masaken Barzah, HamishAutostrade, facing Qasioun Mall, Real Estate No 4/27, Barzeh, Phase 9 | | Counterparty signatory | **Dr. Mona Abd Al Malek**, General Manager (signature + Levant Animal Health corporate seal on signature page; **date field is BLANK on both sides**) | | JAPFA party | **PT VAKSINDO SATWA NUSANTARA** — Jakarta | | JAPFA signatory | **Dr. Teguh Yodiantara Prajitno**, President Director | | Agreement type | Distributorship Agreement — standard Vaksindo template, lightly tailored to Syria | | Effective date | **1 April 2024** (per recital — filename "05.04.2024" reflects 5 April, the executed date) | | **Term end** | **1 April 2027** — ~11 months from this review | | Territory | **Syria** (Art. 1.13) | | Exclusivity | **CONTRADICTORY** — Art. 2.1 says "non exclusive" AND "exclusively in the Territory" in the same sentence; Art. 5 (heading "Non-Exclusivity") then imposes export and use limits on the Distributor | | Delivery basis | **CIF Beirut International Airport** (Lebanon — not Damascus) | | Currency | **USD** — pre-payment in cash, 7 days from pro-forma invoice, **before shipment** | | Governing law | **Indonesian law** (Art. 34.1) — good | | Forum | **HYBRID defect** — *"BANI (Badan Arbitrase Nasional Indonesia) or in accordance with the arbitration rules of the Singapore International Arbitration Centre ('SIAC Rules')"* (Art. 34.2) — same defect as MENA Agrovet, Pakistan UMEX, Egypt 5Stars, others | | Bilingual | **English-only** — UU 24/2009 info-only for outbound; Syrian Arabic-language law is the live risk | | Schedule A | 3-year volume table by SKU + CIF USD price; 10% annual upward revision; total Year-1 ~ USD 235K, Year-2 ~ USD 259K, Year-3 ~ USD 285K | | Letter of Authorization | Present (Draft folder, undated); covers 17 Vaksimune SKUs; valid until **1 April 2027** (mirrors agreement term); signed by Dr. Teguh Y. Prajitno only — **counterparty has not countersigned** | | Sibling file in same folder | `Signed Distribution Agreement AL HAYTHAM - Syria.pdf` — verified by OCR of pages 1 & 15-16: **same legal entity, same text, same effective date, same signatures.** It is the scanned signed counterpart of the same agreement (not a separate counterparty as the filename might suggest). | --- ## Score and Grade — **52 / 100 — Grade D** **Verdict:** Significant rework. The contract is operative and JAPFA is broadly protected on the commercial substance, but four structural defects collide with Syria-specific local-law exposure to produce a sub-baseline score. Renewal in April 2027 is the natural moment to fix — but two of these need attention BEFORE that (sanctions exit + Arabic translation for enforceability). **Traffic light:** RED. **Confidence:** **High.** PDF was fully text-searchable; full 17-page contract + Schedule A + LOA all read end-to-end. ### Section Breakdown | # | Section | Score | Weight | Rationale (cite benchmark row) | |---|---------|-------|--------|--------------------------------| | 1 | Territory, exclusivity & multi-distributor permissibility | **6 / 12** | 12 | Art. 2.1 contradicts itself ("non exclusive… exclusively in the Territory"). Art. 5 heading says "Non-Exclusivity" but then imposes one-way restrictions ON the Distributor only. **No JAPFA-side carve-out** for online, government tender, direct sale, or appointment of additional distributors. Per benchmark §1, market is "JAPFA retains right to appoint other distributors in territory" — silent here. **Practical answer to multi-distributor question: AMBIGUOUS / LITIGATION-RISK** — Distributor could argue Art. 5 read together with Art. 2.1 grants de facto exclusivity. Pakistan UMEX equivalent scored higher because its template said "non-exclusive" clean. | | 2 | Pricing, payment & FX | **8 / 10** | 10 | **Strong for JAPFA**: pre-shipment USD cash within 7 days of pro-forma (Art. 9.1) — best-in-portfolio payment structure. Tax gross-up present (Art. 9.5). Annual price review with FX trigger (Art. 3.2). One Syria-specific risk: Art. 3.4 acknowledges Syrian government may set prices — this is a **circuit-breaker disguised as a routine clause**. If the Syrian Ministry of Health/Agriculture imposes a price ceiling below CIF cost, the contract gives JAPFA no exit. | | 3 | Time-tiered discounts & rebates | **3 / 6** | 6 | **No discount / rebate mechanism at all.** Schedule A is a price + volume schedule, not a tier table. Per benchmark §3 a year-by-year tier with paid-invoice trigger is standard — absent here. Not a deal-killer because pre-payment in cash limits credit risk, but JAPFA loses the year-over-year incentive lever to push the Distributor onto larger volumes. | | 4 | Sales targets & minimums | **6 / 8** | 8 | Schedule A provides Year-1, Year-2, Year-3 minimums per SKU with 10% annual escalator. Take-or-pay mechanism via Art. 7.2 (Distributor liable for shortfall OR termination — Supplier elects). Above benchmark §4. One gap: Art. 7.1 measures the "year" from "the date of registration of Products in the Territory" not the Effective Date — so if registration is delayed, the minimum-purchase clock never starts. | | 5 | Termination, post-term & **Syria mandatory termination compensation** | **6 / 14** | 14 | (a) **No KUHPerdata Art. 1266/1267 waiver** (per benchmark §5 standard JAPFA-favored clause; absent — JAPFA must go to court to terminate under Indonesian-law default). (b) Cure period is 60 days for material breach (Art. 23.2.e) — generous to Distributor; market is 30 days. (c) **Syrian Commercial Agencies Law No. 12/2010 imposes mandatory indemnity on termination** for registered distributors (Topic 5 + Syria country note). The contract does not address Syria-side compensation, does not require Distributor's warranty against commercial-agent registration, and does not specify a 5-year minimum term as Syrian law typically expects (this is a 3-year contract). Real exposure if JAPFA non-renews in 2027. (d) Stock buy-back: 6-month sell-off (Art. 24.2) is fine, but no JAPFA right to repurchase at COGS. (e) MA recoverability: Art. 4 has a partial bailee construction (good), but Art. 24.5 requires Distributor cooperation within 30 days of request — Syrian DOAH practical reality is 6-12 months. | | 6 | Registration / MA / NIE ownership & practical recoverability | **8 / 12** | 12 | **Above market**: Art. 4.2 contains the **bailee construction** ("Distributor… shall act solely as a bailee to Supplier's registration") — one of the strongest MA preservation clauses in JAPFA's portfolio. Art. 4.5 requires Distributor to surrender usage rights at no cost. Art. 24.5 obliges Distributor to withdraw and to cooperate in inserting JAPFA's new nominee. **Practical recoverability discount** for Syria: chaotic post-Assad-transition Directorate of Veterinary Medicine + 6-12 month approval cycle + no centralized online portal mean even a perfectly drafted transfer-back clause may take 9-15 months in practice. **Dossier ownership** clean (Art. 4.3). | | 7 | International dispute & **enforceability in Syria** | **5 / 14** | 14 | **HYBRID/PATHOLOGICAL dispute clause (Art. 34.2)** — see Critical Risk #1. Same defect as MENA Agrovet (Grade F), Pakistan UMEX, Egypt 5Stars. The "BANI **or** SIAC Rules" wording is operationally broken: BANI runs BANI Rules; SIAC runs SIAC Rules. **Enforcement in Syria**: post-Assad transition, Syrian courts are reorganizing. Syria IS a NY Convention signatory (acceded 1959 — verify current status), but practical enforcement of foreign awards is presently chaotic. Syrian Article 5/1967 may impose public-policy escape. **No language clause** — Arabic-language law applies to any state-court enforcement in Syria, so an SIAC award would need certified Arabic translation. **No CISG exclusion** — Syria's CISG status is unclear (likely not signatory; verify); Indonesia is not, so by default CISG should not apply, but expressly exclude. | | 8 | IP, confidentiality & non-compete | **5 / 6** | 6 | Confidentiality survives 5 years (Art. 16.5) — at market. IP clauses (Art. 11) clean — Distributor reports infringement, Supplier owns IP. Trademark licence revocable + non-transferable (Art. 10.1). Non-compete during term only — no post-term non-compete, which is acceptable for distribution. One gap: Art. 12.2 requires JAPFA approval of marketing materials but is silent on response deadline — invites Distributor stall. | | 9 | Liability, indemnity & compliance reps (sanctions/Bahasa excluded) | **3 / 8** | 8 | **Art. 21.4 caps JAPFA liability at "the price actually paid by the Distributor… during the one month prior to the occurrence of the breach"** — about USD 20K-25K based on Schedule A monthly run-rate. Far below benchmark §8 (12 months Net Sales). Same defect as MENA Agrovet, Algeria BMB, etc. + missing standard carve-outs (death/personal injury, fraud, willful misconduct, anti-bribery). Indemnity asymmetric — Art. 21.1 is **Distributor-side only against JAPFA**; no reciprocal indemnity from JAPFA for IP infringement of supplied products (only a "best knowledge" warranty in Art. 20.3). Ethics & anti-bribery (Art. 25.1) present but minimal — no FCPA/UKBA reference, no audit right. | | 10 | Counterparty-country voidance risks & misc boilerplate | **2 / 10** | 10 | **Syria-specific gaps stack up**: (a) **Sanctions overlay** — Syria is a tier-1 sanctions country; despite OFAC GL 24 authorizing veterinary exports post-Assad transition, contract has **no sanctions screening, no sanctions exit clause, no warranty on counterparty UBO**. (b) **No Arabic translation requirement** — required for Syrian state-court enforcement. (c) **No commercial registry filing acknowledgement** — Ministry of Industry registration for exclusive distributors is mandatory under Law 12/2010 to be enforceable. (d) **No FX repatriation acknowledgment** — Central Bank of Syria requires 180-day repatriation undertaking via CBS-approved banks; contract silent. (e) **Force Majeure (Art. 28)** is too broad — includes "labor disturbance/disputes" and "shortage of raw materials required to manufacture the products," which lets Distributor walk on operational excuses. (f) **No Hague apostille / consular legalization clause** — Syria is not a Hague Apostille member, consular legalization typically required for foreign documents. (g) **CIF point is Beirut Airport (Lebanon)** — adds a Lebanese transit risk and Lebanese customs touchpoint, not addressed in title-transfer or risk-of-loss clauses. | | | **Total** | **52 / 100** | 100 | Grade D | ### Score Drivers **Largest negative drivers:** - **Section 7 — Hybrid BANI+SIAC dispute clause**: -8 points (pathological defect, NY Convention Art. V(1)(d) refusal risk; per case-law-principles Topic 6) - **Section 9 — 1-month liability cap**: -5 points (benchmark §8 walk-away) - **Section 5 — Syrian commercial-agency-law termination compensation exposure**: -5 points (Law 12/2010 mandatory indemnity; per Topic 5 + Syria country note) - **Section 10 — No sanctions exit clause in tier-1 country**: -3 points (per international-dispute.md sanctions exit guidance) - **Section 10 — Force Majeure too broad**: -3 points (includes labor disputes + raw-material shortage) - **Section 5 — No KUHPerdata Art. 1266/1267 waiver**: -3 points (Topic 1) - **Section 1 — Exclusivity/multi-distributor ambiguity**: -3 points (Art. 2.1 self-contradicts; Art. 5 one-sided restrictions) - **Section 10 — No Arabic translation requirement for Syria state-court enforcement**: -2 points - **Section 9 — Adverse event reporting at 10 calendar days**: -2 points (vs market 24h serious / 5d non-serious) - **Section 7 — No CISG exclusion**: -1 point **Largest positive drivers:** - **Section 2 — Pre-shipment USD cash payment (7 days from pro-forma)**: +3 points (strongest payment structure in portfolio) - **Section 6 — Bailee construction for MA + Distributor-cost transfer-back**: +3 points - **Section 7 — Indonesian governing law preserved**: +2 points - **Section 4 — Take-or-pay minimum with 10% annual escalator**: +2 points - **Section 8 — Sub-distribution requires JAPFA written consent (Art. 5.1)**: +2 points - **Section 2 — Tax gross-up clause (Art. 9.5)**: +1 point - **Section 8 — 5-year confidentiality survival**: +1 point ### Score Trajectory if Negotiated - If JAPFA wins the top 3 priorities in renewal (clean SIAC clause, 12-month liability cap, Syria-specific sanctions exit + commercial-agency disclaimer): **~70 / 100 — Grade B** (operationally workable). - If JAPFA accepts as-is at renewal: **stays 52 / D**, plus elevated termination-compensation exposure from longer running tenure under Syrian Law 12/2010. - If JAPFA wins everything including Arabic-bilingual instrument + clean exclusivity clause + commercial-registry registration + FCPA/UKBA reps: **~78 / 100 — Grade B+**. --- ## Plain-English Executive Summary **The deal in 3 sentences:** JAPFA (PT Vaksindo Satwa Nusantara) appointed Al Haytham for Trade — trading as Levant Animal Health — as its veterinary-vaccine distributor in **Syria** for **3 years from 1 April 2024 to 1 April 2027**, delivering CIF to **Beirut Airport** (Lebanon, not Damascus), against **pre-paid USD cash within 7 days of pro-forma invoice**. Minimum purchases for Schedule A's 13 Vaksimune SKUs grow from USD ~235K (Year 1) to USD ~285K (Year 3) with a 10% annual escalator. The contract is governed by Indonesian law and has been signed and stamped by both sides (counterparty signature dates blank). **The single most important thing JAPFA needs to know:** The deal is operating and the commercial substance is broadly OK — **JAPFA gets paid up-front, owns the registration via a bailee construction, and retains Indonesian governing law.** But four template defects (hybrid dispute clause, 1-month liability cap, contradictory exclusivity, missing 1266/1267 waiver) collide with four Syria-specific gaps (no sanctions exit, no Arabic translation, no commercial-registry acknowledgement, no FX repatriation acknowledgment) to push the score to D. **The contract expires 1 April 2027 (~11 months) — that is the natural cleanup window. Two issues need attention BEFORE then.** **Five biggest problems and what to do about each:** 1. **The dispute clause is internally broken (Article 34.2).** It says "BANI **or** SIAC Rules" — picking either the Jakarta arbitration body's rulebook or Singapore's. At enforcement time, the losing side has a textbook NY Convention Article V(1)(d) defense ("composition of the arbitral authority was not in accordance with the agreement of the parties"). For Syria specifically — where post-Assad transition courts are still reorganizing — a broken arbitration clause means JAPFA has **no realistic path to enforce** a foreign award if Levant Animal Health defaults. **Action: Side-letter NOW (don't wait for renewal) electing one forum — recommend clean SIAC Singapore + English + 3 arbitrators. Add KUHPerdata 1266/1267 waiver and CISG exclusion at the same time.** 2. **The liability cap is one MONTH of purchase price (Articles 21.3 and 21.4).** That's roughly USD 20-25K based on Schedule A's monthly run-rate. Two cascading problems: (a) if a JAPFA-side product issue causes a Syrian recall and an Indonesian arbitrator finds the cap unconscionable under KUHPerdata Art. 1338, JAPFA ends up with NO cap; (b) conversely, if Levant mishandles JAPFA's Syrian DOAH registration and JAPFA loses Syria market access for 12-24 months, JAPFA can only recover ~USD 20-25K. The cap also lacks standard carve-outs. **Action: In renewal (Q4 2026), replace with 12-month Net Sales mutual cap with carve-outs for IP infringement, recall, death/personal injury, willful misconduct, fraud, anti-bribery, and confidentiality breach.** 3. **No sanctions exit clause in a tier-1 sanctions country.** Post-Assad transition has cleared most Syria sanctions — OFAC GL 24 authorizes veterinary exports, EU Regulation 2024/3197 allows vet med exports with end-use certificates, and JAPFA compliance has cleared the relationship. **But sanctions can re-tighten.** The current Trump administration policy stance on Syria is fluid; a new SDN designation against the counterparty or any UBO would immediately expose JAPFA to OFAC secondary-sanctions risk on USD wire payments. The contract has no unilateral JAPFA termination right on a sanctions trigger. **Action: Side-letter NOW (before renewal) adding a JAPFA-side unilateral termination right on Levant or any UBO becoming a Sanctioned Person, OR on performance becoming illegal under OFAC/EU/UN sanctions. Draft text in Appendix A.** 4. **Syrian commercial agency law (Law 12/2010) imposes mandatory indemnity on registered distributors at termination — and the contract is silent on it.** Syrian law expects exclusive distributors to register with the Ministry of Industry; registered distributors have mandatory indemnity rights on termination/non-renewal; and Syrian law typically anchors to a **5-year minimum** for registered exclusive distribution. This is a 3-year contract. If JAPFA non-renews on 1 April 2027 without Levant's consent and Levant has registered as a commercial agent in Syria, JAPFA could face an indemnity claim. **Action: Within 60 days, ask Levant in writing whether they have registered the agreement (or themselves as commercial agent) at the Syrian Ministry of Industry. Document the answer. In renewal, add an express waiver of Syrian commercial-agency-law termination compensation, and a warranty by Distributor that they will not register without JAPFA's written consent.** 5. **Force Majeure is dangerously broad (Article 28).** It includes "labor disturbance/disputes," "strikes or lock-outs," and "shortage of raw materials required to manufacture the products." Under Indonesian KUHPerdata Arts. 1244-1245 + Topic 3, economic hardship is NOT supposed to be FM — but the language here is broader than market. A Syrian importer facing FX scarcity, fuel shortage, or labor unrest could invoke FM to walk away from minimum-purchase obligations. **Action: In renewal, narrow FM to acts of God + war + government export bans on the supplier side. Exclude labor disputes, raw-material shortages, and any economic/currency hardship.** **Three more things worth knowing:** - **Both signature dates are blank.** Contract is signed and stamped (Levant corporate seal visible on the OCR'd scanned counterpart), but neither party dated their signature. Effective Date is 1 April 2024 per the recital. Not fatal — but if a counterparty ever contests effective date, JAPFA has weak documentary evidence. - **CIF delivery point is Beirut Airport (Lebanon), not Damascus.** This adds a Lebanese customs touchpoint and a transit risk between Beirut and Damascus that the contract does not address (title transfer, risk of loss, insurance scope between airport and final destination). - **Adverse event reporting at 10 calendar days (Art. 13.6) is below market.** Standard for veterinary biologics is 24 hours for serious AEs and 5 days for non-serious. If a Syrian vet reports a serious reaction and Levant takes the full 10 days to forward to JAPFA, that delay could constitute a pharmacovigilance compliance failure for JAPFA's other markets. **The Al Haytham sibling PDF is the same agreement, not a different counterparty.** The folder contains a second file `Signed Distribution Agreement AL HAYTHAM - Syria.pdf` (image-only scan). OCR confirms: same recital, same parties, same Effective Date 1 April 2024, same Article 34, same signatures of Dr. Teguh Yodiantara Prajitno and Dr. Mona Abd Al Malek. The contract names the entity as "AL HAYTHAM FOR TRADE LIMITED LIABILITY COMPANY (LEVANT ANIMAL HEALTH)" — one legal entity, two trading names. **Bottom line — verdict:** **Negotiate before signing — but you've already signed.** The contract is operative and the commercial substance is OK. **Two side-letter items now (sanctions exit + clean dispute clause)**, plus a clean re-paper at the April 2027 renewal moment to fix the structural and Syria-specific gaps. --- ## Top Red Flags ### CRITICAL — 1. Article 34.2 hybrid forum defect (BANI **or** SIAC Rules) **Severity:** Critical **Verbatim quote:** *"Failing that, the Parties agree to bring the dispute to BANI (Badan Arbitrase Nasional Indonesia) or in accordance with the arbitration rules of the Singapore International Arbitration Centre ('SIAC Rules')"* **Issue:** Two arbitration paths in one disjunctive sentence — BANI (Jakarta institution + BANI Rules) OR SIAC Rules (Singapore institution + SIAC Rules). The "or" is fatal: neither party is bound to a specific institution or seat, and the wording is not a valid agreement to arbitrate at either. At enforcement, the losing side has a textbook NY Convention Article V(1)(d) defense — "the composition of the arbitral authority or the arbitral procedure was not in accordance with the agreement of the parties." Same defect identified in MENA Agrovet, Pakistan UMEX, Egypt 5Stars and several others — it is a portfolio-wide template bug. **Plain English (what this means in business terms):** If Levant defaults on a USD 250K minimum-purchase obligation or refuses to return JAPFA's Syrian DOAH registration, JAPFA can't pin down which arbitration body to file with. Worse, if JAPFA wins a SIAC award and tries to enforce in Syria post-Assad-transition (where courts are presently reorganizing and pro-forma), Levant can refuse to honor it by pointing to Article 34.2's ambiguity and arguing JAPFA chose the wrong institution. Realistic exposure: 12-24 months of enforcement litigation with no guaranteed outcome. **What you should do (exact action):** 1. **Within 30 days:** Send a side-letter to Levant Animal Health electing **SIAC Singapore + English + 3 arbitrators** as the exclusive forum, with seat = Singapore. Owner: JAPFA Legal. 2. **At renewal (Q4 2026):** Replace Art. 34.2 entirely with the clause below. **Suggested replacement clause text:** > *"Any dispute, controversy or claim arising out of or relating to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof, shall be referred to and finally resolved by arbitration administered by the Singapore International Arbitration Centre ("SIAC") in accordance with the Arbitration Rules of SIAC for the time being in force, which rules are deemed to be incorporated by reference in this clause. The seat of arbitration shall be Singapore. The Tribunal shall consist of three (3) arbitrators. The language of the arbitration shall be English. The 1980 United Nations Convention on Contracts for the International Sale of Goods is expressly excluded. The Parties expressly waive Articles 1266 and 1267 of the Indonesian Civil Code (KUHPerdata)."* --- ### CRITICAL — 2. Liability cap of ONE MONTH of purchase price (Articles 21.3 and 21.4) **Severity:** Critical **Verbatim quote:** - Art. 21.3: *"…in no event will Supplier be liable for any loss of profits, loss of use, business interruption, or costs of procurement of substitute goods, cost for punitive or exemplary, or indirect, special, incidental or consequential damages of any kind…"* - Art. 21.4: *"Supplier's liability under this agreement or the termination of this agreement will not, in any event, exceed the price actually paid by the Distributor to Supplier pursuant to this agreement during the one month prior to the occurrence of the breach or damage."* **Issue:** One-month cap on JAPFA's liability — roughly USD 20-25K based on Schedule A's monthly run-rate of ~USD 20K (Year 1). Cap is mutual via Art. 29's general limitation, but the specific one-month formula in 21.4 also applies. No standard carve-outs (no IP, no recall, no death/personal injury, no fraud, no willful misconduct, no anti-bribery, no confidentiality breach). **Plain English (what this means in business terms):** Two ways this hurts JAPFA: - **(a) Cap can be struck down**: If a JAPFA product issue causes a Syrian recall and an Indonesian arbitrator views the one-month cap as unconscionable under KUHPerdata Art. 1338 (good-faith requirement), the cap is gone and JAPFA faces uncapped exposure (potentially USD multi-million on a major poultry recall). - **(b) Cap also limits Levant's exposure**: If Levant mishandles JAPFA's Syrian DOAH MA registration — say, lets it lapse during a non-renewal scenario — JAPFA can only recover ~USD 20-25K from Levant. Replacing market access in Syria takes 6-12 months minimum (per Syria country profile), worth much more than USD 25K. **What you should do (exact action):** 1. **At renewal (Q4 2026):** Replace Art. 21.4 with a mutual 12-month Net Sales cap and standard carve-outs. 2. **No pre-renewal action** unless a real liability event occurs — the cap is mutual, so the current under-capping is symmetrical and not immediately threatening. 3. **Owner:** JAPFA Legal. **Suggested replacement clause text:** > *"Each Party's aggregate liability arising out of or relating to this Agreement shall not exceed twelve (12) months of Net Sales calculated as the aggregate purchase price paid by Distributor under this Agreement in the twelve (12) months preceding the event giving rise to the claim. The foregoing cap shall not apply to: (a) death or personal injury; (b) fraud; (c) willful misconduct; (d) breach of confidentiality; (e) intellectual property infringement; (f) product recall costs arising from willful misconduct or gross negligence; (g) anti-bribery or sanctions breach; (h) breach of payment obligations; or (i) any liability that cannot lawfully be limited under Indonesian law."* --- ### CRITICAL — 3. No sanctions exit clause for a Tier-1 sanctions overlay country **Severity:** Critical **Verbatim quote:** None — clause is **absent**. **Issue:** Syria sits on JAPFA's "Tier-1 sanctions overlay country" list alongside Iran, Russia, North Korea, Belarus, Cuba. Post-Assad transition has cleared most pre-2024 sanctions — OFAC GL 24 authorizes veterinary exports (verified Syria country note), EU Regulation 2024/3197 allows vet med exports with end-use certificates — and JAPFA compliance has cleared the Levant relationship. **But sanctions snap back fast.** Recent precedent: Russia 2022 sanctions hit JAPFA's Vet Zoo Russian counterparty's bank (Alfa-Bank) overnight, leaving JAPFA with a frozen wire and no contractual exit. Syria is presently fluid — a new SDN designation against Levant's UBO, officers, or bank would expose JAPFA to OFAC secondary-sanctions risk on USD wire payments (50 USC § 1701 et seq., IEEPA). The contract has no JAPFA-side unilateral right to terminate or suspend on a sanctions trigger. **Plain English (what this means in business terms):** If a new SDN designation hits Levant's UBO or a bank in the payment chain after this Monday, every USD wire JAPFA processes from then onward could be treated by US Treasury as "doing business with a sanctioned entity." Penalties up to USD 10M+ per occurrence + US banking blacklist. **Without a sanctions exit clause, JAPFA cannot terminate Levant without breach exposure** — JAPFA would face a contract claim from Levant on top of the OFAC exposure. **What you should do (exact action):** 1. **Within 30 days:** Side-letter to Levant Animal Health adding the sanctions exit clause below. Owner: JAPFA Legal + JAPFA Compliance. 2. **Annual screening obligation:** Run OFAC SDN + EU + UN screening on Levant + officers + bank counterparties annually; document in compliance file. **Suggested clause text (side-letter + renewal):** > *"Sanctions Exit. JAPFA may terminate this Agreement immediately upon written notice if (a) Distributor or any of its directors, officers, ultimate beneficial owners, or contractually-engaged banks becomes a Sanctioned Person, or is owned 50% or more by a Sanctioned Person; or (b) the performance of this Agreement would cause JAPFA to violate any applicable sanctions regime administered by the US Office of Foreign Assets Control, the European Union, the United Nations Security Council, or the United Kingdom. 'Sanctioned Person' means any person or entity (i) listed on OFAC's Specially Designated Nationals and Blocked Persons List, the EU consolidated sanctions list, or the UN Security Council sanctions list, or (ii) the government, agency or instrumentality of, or organized under the laws of, any country subject to comprehensive sanctions. Distributor warrants that as of the date of this side-letter and on each shipment date, Distributor and its UBOs are not Sanctioned Persons."* --- ### HIGH — 4. Syrian Commercial Agencies Law No. 12/2010 termination compensation exposure **Severity:** Material (potentially Critical if Levant has already registered) **Verbatim quote:** None — Syrian commercial-agency-law silence is the issue. **Issue:** Syrian Commercial Agencies Law No. 12/2010 (still applicable post-Assad transition per Syria country note) imposes: - Mandatory **Ministry of Industry registration** for exclusive distributors to be enforceable - **5-year minimum contract** expectation for registered exclusive distribution (this contract is 3 years) - **Mandatory indemnity on termination** for registered distributors The contract does not (i) require Levant to disclose whether it has registered as a commercial agent, (ii) prohibit Levant from registering without JAPFA's consent, (iii) expressly disclaim Syrian commercial-agency-law application, or (iv) cap any termination compensation. **Plain English (what this means in business terms):** On 1 April 2027 (renewal moment), if JAPFA decides to non-renew and appoint a different Syrian distributor, and Levant has registered with the Syrian Ministry of Industry as JAPFA's exclusive commercial agent, Levant can claim mandatory indemnity under Law 12/2010. Exposure scale: typical Middle East commercial-agency indemnities range from 1-3 years of average commissions / profits. On a contract with ~USD 285K annual sales value, that could be USD 100K-300K exposure on top of the lost contract. **What you should do (exact action):** 1. **Within 60 days:** Send a written question to Levant Animal Health: *"Please confirm whether Al Haytham for Trade Limited Liability Company / Levant Animal Health has registered (i) the Distributorship Agreement dated 1 April 2024, or (ii) itself as a commercial agent of PT Vaksindo Satwa Nusantara, with the Syrian Ministry of Industry or any other Syrian governmental authority. If yes, please provide registration number and date."* Document the answer in writing. Owner: JAPFA Legal. 2. **In renewal (Q4 2026):** Add an express waiver and warranty: > *"The Parties agree that Distributor is appointed as an independent distributor purchasing and reselling on its own account, NOT as a commercial agent. Distributor warrants that it has not registered, and will not register, this Agreement or itself as a commercial agent of Supplier with the Syrian Ministry of Industry or any other authority without Supplier's prior written consent. The Parties expressly disclaim the application of Syrian Commercial Agencies Law No. 12 of 2010 to this Agreement. Any termination of this Agreement in accordance with its terms shall give rise to no indemnity, compensation, or goodwill payment from Supplier to Distributor."* --- ### HIGH — 5. Exclusivity / multi-distributor permissibility is contradictory **Severity:** Material **Verbatim quote:** - Art. 2.1: *"Supplier… hereby appoints Distributor, on a **non exclusive** and principal to principal basis, as its distributor for the promotion, sale and distribution of the Products and **exclusively in the Territory** only during the term of Agreement."* - Art. 5 heading: *"Non-Exclusivity"* - Art. 5.1: *"Distributor shall not… directly or indirectly market, promote, source, distribute… the Products (a) Outside the Territory; or (b) inside the Territory for use other than as permitted in this Agreement."* **Issue:** Art. 2.1 says "non exclusive" AND "exclusively in the Territory" in the same sentence. Art. 5 is titled "Non-Exclusivity" but only imposes restrictions on the Distributor (a one-way carve-out) — there is no corresponding statement that JAPFA may appoint other distributors in Syria. Drafting is ambiguous: Levant could argue the contract grants de facto territorial exclusivity (since Art. 2.1 says "exclusively in the Territory") and combine it with the LOA (which authorizes Levant alone) to make the case. JAPFA could counter that Art. 2.1's leading words "non exclusive" govern. **Plain English (what this means in business terms):** **Can JAPFA appoint a second distributor in Syria today?** **AMBIGUOUS** — and the ambiguity creates litigation risk if JAPFA tries. Combined with the Syrian Commercial Agencies Law 12/2010 stickiness (Risk #4 above), JAPFA's effective ability to appoint a second Syrian distributor before April 2027 is **CONDITIONAL** at best: JAPFA would need (i) Levant's written consent, OR (ii) a carve-out side-letter clarifying the non-exclusive interpretation, OR (iii) acceptance of termination-compensation exposure. **What you should do (exact action):** 1. **Side-letter or interpretation memo (now)**: If JAPFA wants the option to appoint a second Syrian distributor before April 2027, send Levant a side-letter confirming: *"For the avoidance of doubt, the Parties acknowledge that the appointment of Distributor under Article 2.1 is non-exclusive, and Supplier reserves the right to appoint additional distributors and to sell directly within the Territory at its discretion, subject to Distributor's right to perform its existing obligations."* 2. **At renewal:** Rewrite Article 2.1 cleanly — choose ONE: clearly non-exclusive, clearly exclusive, or exclusive with carve-outs (online channel, government tender, JAPFA direct sale). Apply matching language in Article 5. 3. **Owner:** JAPFA Legal + JAPFA Commercial. --- ### MATERIAL — 6. KUHPerdata Article 1266/1267 waiver missing **Severity:** Material **Verbatim quote:** None — clause is absent. **Issue:** Under Indonesian law default (KUHPerdata Articles 1266/1267 — "you can't simply walk away from a contract; you'd have to go to court first to get permission to terminate"), even when Article 23.2 lists material-breach termination rights, JAPFA technically needs a court ruling to terminate unless the Parties expressly waive Articles 1266/1267. Common JAPFA-template defect. **Plain English (what this means in business terms):** If Levant materially breaches (e.g., refuses to transfer MA at termination), JAPFA cannot just send a notice and walk — JAPFA must file in an Indonesian court for a 1266 cancellation order. That adds 6-18 months of litigation before JAPFA's termination is "effective" under Indonesian law. The bigger practical problem: the BANI/SIAC dispute clause in Article 34 doesn't help because 1266/1267 is a substantive Indonesian-law rule, not a procedural one. An arbitrator applying Indonesian law would have to give effect to 1266. **What you should do (exact action):** 1. **Side-letter (combine with Risk #1 and #3)** adding the standard one-line waiver. Owner: JAPFA Legal. 2. **At renewal:** Bake into Article 34 (see suggested replacement under Risk #1). **Suggested clause text:** > *"The Parties expressly waive the application of Articles 1266 and 1267 of the Indonesian Civil Code (KUHPerdata) such that no court order shall be required to effect termination of this Agreement in accordance with its terms."* --- ### MATERIAL — 7. Force Majeure scope is too broad (Article 28) **Severity:** Material **Verbatim quote:** *"…act of God; war or insurrection; civil commotion; destruction of essential facilities or materials by earthquake, fire, flood or storm; **labor disturbance/disputes; strikes or lock-outs**, epidemic; or other similar event; **shortage of raw materials required to manufacture the products**…"* **Issue:** Force Majeure includes labor disturbances/strikes AND raw-material shortages. Under benchmark §10 and Topic 3 (case-law-principles), market-standard FM is narrow — acts of God + war + government export bans on the supplier side. Labor disputes and raw-material shortages are foreseeable operational risks, not FM. The 30-business-day FM termination right (Art. 28 last sentence) means Levant could invoke a 4-week Syrian fuel shortage or import-license delay as FM and walk from minimum-purchase obligations. **Plain English (what this means in business terms):** Syria has chronic FX, fuel, and labor instability post-Assad-transition. If a Syrian dock workers' strike delays a shipment, or if Levant's regional supply chain hiccups, Levant can invoke FM and avoid the Schedule A take-or-pay obligation for months — leaving JAPFA holding produced stock with no buyer. **What you should do (exact action):** 1. **At renewal:** Replace FM definition with narrower scope. 2. **Owner:** JAPFA Legal. **Suggested replacement clause text:** > *"For purposes of this Agreement, 'Force Majeure' means an event beyond the reasonable control of the affected Party that could not have been prevented by the exercise of reasonable diligence, limited to: (a) acts of God (earthquake, fire, flood, storm); (b) war, armed conflict, terrorism, or insurrection; (c) genuine epidemic or pandemic declared by the World Health Organization; (d) government export ban or sanction directly preventing performance by the supplier-side Party. For avoidance of doubt, Force Majeure does NOT include: (i) labor disputes affecting the affected Party's own workforce; (ii) raw-material shortages; (iii) currency fluctuations or foreign-exchange controls; (iv) regulatory delay foreseeable as of the Effective Date; (v) economic hardship. The Party invoking Force Majeure shall give written notice within seven (7) Business Days. If Force Majeure persists more than ninety (90) Business Days, either Party may terminate."* --- ### MATERIAL — 8. Adverse event reporting timing (Article 13.6) **Severity:** Material **Verbatim quote:** *"Distributor shall inform Supplier of all Product complaints or inquiries related to quality or technical-related complaints respecting all Product within **ten (10) calendar days** of receipt of such complaint or inquiry…"* **Issue:** 10 calendar days for all AE reporting is below market for veterinary biologics. Benchmark §6 standard is 24 hours for serious AEs and 5 days for non-serious. JAPFA's pharmacovigilance obligations to BPOM (Indonesia), EMA-equivalent in EU markets, FDA-equivalent in others, depend on rapid signal detection — a 10-day reporting lag means JAPFA learns of a Syrian AE 10 days after Levant did, then takes its own analysis time, then reports late. **Plain English (what this means in business terms):** A Syrian vet reports a serious anaphylactic reaction to a vaccinated flock; under this contract Levant can sit on the report for 10 days. By then JAPFA's other markets may have similar reactions, and JAPFA's pharmacovigilance regulator audit could find JAPFA in breach of its own reporting timelines. Exposure: regulatory finding + product registration suspension risk in any market with stricter PV rules. **What you should do (exact action):** 1. **In renewal:** Tighten to 24h serious / 5 days non-serious + an explicit definition of "serious." 2. **Owner:** JAPFA Veterinary + JAPFA Legal. **Suggested replacement clause text:** > *"Distributor shall report to Supplier (a) **Serious Adverse Events** (death, life-threatening condition, persistent disability, congenital anomaly, or other clinically significant outcome) within **twenty-four (24) hours** of becoming aware; and (b) **Non-Serious Adverse Events and all Quality Complaints** within **five (5) Business Days**. Reports shall be sent in writing to pharmacovigilance@japfa.com with copy to Supplier's Quality Assurance head. Distributor shall preserve all original complaint documentation for not less than ten (10) years."* --- ### MINOR — 9. Counterparty signature undated **Severity:** Minor **Issue:** Both signature blocks (page 16) leave the "Date" field blank. Effective Date is fixed at 1 April 2024 by recital, but if the parties signed materially later, that creates a small evidential gap for any clause keyed to "Effective Date + N days" (e.g., Art. 17.6 15-day label specifications, Art. 17.12 15-day post-registration launch). **What you should do:** - **Note in file. No formal action needed**, but at renewal use a side-letter to ratify the actual execution date and capture board authorization. --- ### MINOR — 10. CIF delivery point is Beirut Airport, Lebanon (Art. 3.1) **Severity:** Minor **Issue:** CIF Beirut creates a Lebanese customs touchpoint and an unaddressed Beirut-to-Damascus land transit risk. Title and risk of loss under INCOTERMS 2020 CIF transfer at Beirut Airport; the contract does not address transit from Beirut to Damascus. **What you should do:** - **In renewal:** Either (a) move CIF point to Damascus (if possible post-transition) or (b) add a clause confirming title and risk transfer at Beirut Airport and requiring Distributor to maintain in-transit insurance Beirut-to-Damascus. --- ## Negotiation Priority Stack ### Priority 1 — Side-letter fixing Article 34.2 hybrid dispute clause - **Negotiability:** **High** — this is a clear template error; reasonable counterparties accept correction. - **Plain English — why JAPFA should care:** Without a clean arbitration clause, JAPFA has no realistic path to enforce any award in Syrian state courts post-Assad transition. The Russian Vet Zoo experience (2022 sanctions) showed how fast a tier-1 country can become enforcement-hostile. - **Ideal:** Side-letter electing SIAC Singapore + English + 3 arbitrators, with CISG exclusion and KUHPerdata 1266/1267 waiver bundled in. - **Realistic:** Levant accepts as commercially indifferent. - **Walk-away:** Levant refuses → JAPFA proceeds anyway in any future dispute with SIAC + treats Art. 34.2 as silent on institution. - **Leverage:** JAPFA is the sole licensed source of all Vaksimune SKUs in Schedule A; Levant cannot replace JAPFA. - **Focus area:** International dispute resolution + enforceability. - **What to say in the meeting:** *"We've reviewed Article 34.2 and noticed it picks two arbitration regimes at once, which will cause enforcement problems for both of us if a dispute arises. We propose a side-letter electing SIAC Singapore as the single forum. This is administrative cleanup, not a re-negotiation."* ### Priority 2 — Side-letter adding sanctions exit clause - **Negotiability:** **High** — universally accepted in tier-1 countries; Levant should welcome the clarity. - **Plain English — why JAPFA should care:** Syria's sanctions environment is fluid. JAPFA needs a unilateral exit if a new SDN designation hits Levant's UBO or banks. Without it, JAPFA must either keep performing (OFAC exposure) or breach the contract (Levant claim). - **Ideal:** Side-letter with the clause text in Risk #3 above. - **Realistic:** Levant accepts after explanation. - **Walk-away:** Levant refuses → escalate to JAPFA Compliance / Board; consider non-renewal at April 2027. - **Leverage:** OFAC-aware language is industry standard; refusal would signal Levant has UBO/banking concerns worth knowing about. - **Focus area:** Compliance / sanctions. - **What to say in the meeting:** *"As you know, the Syria sanctions landscape changed substantially in late 2024. We need a standard sanctions exit clause to be able to keep operating cleanly under OFAC General License 24. The clause is symmetric in effect — it protects both sides."* ### Priority 3 — Side-letter adding KUHPerdata 1266/1267 waiver - **Negotiability:** **High** — administrative; no commercial impact on Levant. - **Plain English:** Without the waiver, JAPFA must go to Indonesian court to terminate even for clear material breach by Levant. Closes a 6-18-month gap. - **Ideal:** One-line side-letter waiver (text in Risk #6 above). - **Realistic:** Accepted with the Priority 1 + Priority 2 side-letter bundle. - **Walk-away:** None — JAPFA can live without if needed. - **Focus area:** Termination mechanics. - **What to say:** Bundle into the same side-letter as Priority 1. ### Priority 4 — Written question about Syrian Ministry of Industry registration - **Negotiability:** **High** — JAPFA is asking a factual question, not amending the contract. - **Plain English:** JAPFA needs to know its exposure to Syrian Law 12/2010 termination compensation before April 2027 renewal. - **Ideal:** Levant confirms in writing whether it has registered the agreement or itself as commercial agent. - **Realistic:** Levant answers; if registered, JAPFA reassesses 2027 renewal economics. - **Walk-away:** None — informational only. - **Focus area:** Termination / counterparty-country agency law. - **What to say:** Email or formal letter from JAPFA Legal asking the specific question in Risk #4 above. ### Priority 5 — Renewal restructuring (Q4 2026 — 6 months before term end) - **Negotiability:** **Medium** — renewal is a natural moment to clean up the template, but Levant may push back on stricter clauses if it's been performing well. - **Plain English:** This is the moment to fix the liability cap (one month → 12 months Net Sales), narrow Force Majeure, tighten AE reporting to 24h/5d, clarify exclusivity, add commercial-agency disclaimer, add Arabic translation acknowledgement, fix CIF transit gap, and confirm post-Assad-transition Syrian regulatory pathway. - **Ideal:** Full template refresh with the suggested clause texts above + 5-year term (matches Syrian Law 12/2010 expectation). - **Realistic:** 70% of asks accepted; FM narrowing + liability cap most likely sticking points. - **Walk-away:** Levant refuses MA bailee construction OR refuses to disclaim Law 12/2010 → JAPFA non-renews and starts 12-month MA transfer-back planning Q3 2026. - **Focus area:** All 10. - **What to say:** Schedule a renewal-planning call for September 2026 to walk through the revised draft. ### Priority 6 — Tightening exclusivity language (renewal) - **Negotiability:** **Medium** — Levant will want exclusivity; JAPFA wants flexibility. - **Plain English:** Either commit clean to non-exclusive (so JAPFA can run a second Syrian distributor) or commit to exclusive WITH carve-outs (online direct + government tender + JAPFA-Affiliate sale) AND a 5-year minimum term aligned to Syrian Law 12/2010 AND minimum-purchase escalation. - **Trade pairing:** If JAPFA accepts exclusivity, JAPFA gets stronger minimum-purchase commitments and tighter AE reporting in exchange. - **Focus area:** Multi-distributor permissibility (#9). ### Priority 7 — Beirut-to-Damascus transit clause - **Negotiability:** **High** — administrative. - **Plain English:** Define title/risk transfer at Beirut Airport; require Levant to maintain in-transit insurance for the land leg. - **Realistic:** Accepted; cost is on Levant by default. ### Concession Bank - **Allow 90-day shelf-life shipment minimum** (currently 12 months minimum — Art. 13.1) where Levant accepts to use within 30 days post-delivery: shows flexibility, costs JAPFA nothing. - **Quarterly forecast → semi-annual** if Levant prefers: low-value concession. - **Stretch payment from 7 days to 14 days post-pro-forma:** still pre-shipment, costs JAPFA negligible. ### Do-Not-Concede List - **MA bailee construction (Art. 4.2)** — never give this up. - **Pre-shipment USD cash payment (Art. 9.1)** — Syria-specific, the only realistic way to manage Syrian FX risk; never move to open account. - **Indonesian governing law (Art. 34.1)** — never accept Syrian law. - **Sub-distribution requires JAPFA written consent (Art. 5.1)** — Syria post-transition has thin compliance infrastructure; downstream sub-distribution control is essential. - **JAPFA inspection right (Art. 27)** — never give up audit access. --- ## Compliance Review (Indonesian + Syrian + Cross-Border) ### Counterparty-Country Enforceability (Syria) — PRIMARY SECTION #### Question 1 — Will an SIAC or BANI arbitration award be enforced in Syria? - **NY Convention status:** Syria acceded to the 1958 NY Convention in 1959 (verify current status at newyorkconvention.org — post-Assad transition may affect treaty performance). On paper, Syrian courts must enforce foreign arbitral awards subject to Article V grounds. - **Local-court track record:** **Practically chaotic post-Assad transition (late 2024)**. Courts are reorganizing; backlog and unpredictability are high; pre-2024 cases on foreign-award enforcement may not reflect current practice. - **Public-policy / mandatory-law overrides:** Standard Article V(2)(b) public-policy exception is broad under Syrian practice. **Sharia compatibility** review possible on interest/riba and uncertainty/garar terms. - **Language requirement:** Arabic translation of award + underlying contract mandatory for Syrian state-court enforcement. - **Article 34.2 defect compounds:** Even if Syria were enforcement-friendly, Article 34.2's BANI-or-SIAC ambiguity gives the losing side a clean NY Convention Article V(1)(d) refusal ground (composition of arbitral authority not in accordance with parties' agreement). - **Confidence:** **Medium-Low** — Syria's post-transition enforcement framework is in flux. **Verify with Syrian local counsel before relying on award enforcement in Syria.** Practical reality: structure for SIAC Singapore with assets/payments outside Syria (e.g., UAE banking + pre-shipment USD cash), so JAPFA never needs to enforce in Syria. #### Question 2 — Commercial agency law termination compensation (Syria) - **Statute:** **Syrian Commercial Agencies Law No. 12/2010** (still applicable post-Assad transition). - **Exposure formula:** Mandatory indemnity on termination for registered distributors. Typical range 1-3 years' average commissions/profits (verify current case practice). - **Estimated cost to terminate today:** **USD 100K-300K** if Levant has registered. Calculated as 1-3 × Year-1 Schedule A value (USD ~235K) × commission proxy (~30-40%). **Range is wide pending Syrian counsel verification.** - **Is Levant registered as commercial agent?** **UNKNOWN** — contract is silent and Levant has not been asked. **Action: send the written question per Risk #4 above.** - **5-year minimum term expectation:** Syrian law typically anchors registered exclusive distribution to 5-year minimums. This contract is 3 years — Levant could potentially argue under-performance of statutory minimum, though this is a soft argument. - **Confidence:** **Low.** Syrian commercial-agency case law post-transition is unsettled. **Verify with Syrian local counsel.** #### Question 3 — Can JAPFA appoint a second distributor in Syria? - **Answer:** **CONDITIONAL (leaning towards NO without cost)** - **Contract basis:** Article 2.1 is internally contradictory ("non exclusive… exclusively in the Territory"). Article 5 imposes one-sided restrictions on Distributor only. **The contract does not explicitly preserve JAPFA's right to appoint additional distributors.** A Syrian court reading Art. 2.1 + Art. 5 + the LOA (which authorizes Levant alone) could find de facto territorial exclusivity. - **Local-law basis:** Syrian Law 12/2010 — if Levant is registered as exclusive commercial agent, mandatory indemnity attaches to a second appointment without consent. **Local Syrian partner required for imports** — foreign principal cannot register directly (per Syria country note). - **What it would cost:** Depending on Levant's registration status: zero-to-low if not registered (subject to litigation risk over Art. 2.1 interpretation); USD 100K-300K + extended dispute if registered. - **Operational reality:** Pre-April-2027, JAPFA's safest move to enable a second distributor is via Levant's written consent OR via a clean side-letter clarifying the non-exclusive interpretation, OR via the renewal (1 April 2027) clean break. #### Question 4 — Voidance risks in Syrian state court - **Language law:** **Arabic mandatory** for Syrian state-court enforcement. English contract is enforceable as a matter of substantive law via arbitration (SIAC Singapore), but if any enforcement step requires a Syrian court (interim relief, recognition of foreign award), certified Arabic translation is required. Cost: ~USD 1-3K + 2-4 weeks lead time per use. - **Commercial registry filing:** **Mandatory Ministry of Industry registration** for exclusive agency to be enforceable. Contract is silent on whether registration has been made. **Action: Confirm with Levant per Risk #4 above.** - **FX controls:** Central Bank of Syria — **180-day repatriation undertaking** via CBS-approved banks (per Syria country note). Contract does not address. Practical mitigation: pre-shipment USD cash via UAE/Turkey correspondent banking avoids needing to repatriate Syrian-side payment. - **Sharia compatibility:** Syrian civil code is Sharia-influenced for personal-status matters but commercial code is generally civil-law tradition. Late-payment interest (not present in this contract — payment is pre-shipment) and uncertainty (the "as may be mutually agreed" price revision in Art. 3.2) are theoretical exposure points; unlikely to be invoked given the contract structure. - **Local content / Local partner requirement:** **Local Syrian partner mandatory for imports** — foreign principal cannot register directly. Levant fulfills this role; JAPFA cannot bypass without restructuring. - **Sanctions overlay:** Tier-1 sanctions country. Post-Assad transition has cleared most pre-2024 sanctions (OFAC GL 24, EU Reg 2024/3197). **JAPFA compliance has cleared the relationship.** Standing screening obligation: monitor OFAC SDN + EU + UN lists annually for Levant + UBOs + banks. **No live exposure at review time** (May 2026). - **Formalities:** Syria is **NOT a Hague Apostille Convention member** — consular legalization typically required for foreign documents. Contract has no clause on legalization. - **Confidence:** **Medium-Low** — post-Assad transition leaves enforcement chaotic; specific formality requirements need confirmation with Syrian local counsel. ### Indonesian-Side Compliance (SECONDARY) #### Issues found - **KUHPerdata Art. 1266/1267 waiver** — **missing**. Standard JAPFA-favored clause to enable termination without court order. Risk and Fix per Risk #6. - **Adverse event reporting timing (Art. 13.6)** — **10 calendar days too slow** for pharmacovigilance benchmark. Risk and Fix per Risk #8. - **Force Majeure scope (Art. 28)** — too broad. Risk and Fix per Risk #7. - **CISG exclusion** — **missing**. Indonesia is not a CISG signatory (per Topic 7), so by default CISG should not apply, but expressly exclude. Bundle into side-letter (Risk #1 clause text). - **Sanctions screening + UBO warranty** — **missing for tier-1 country**. Risk and Fix per Risk #3. #### Items NOT flagged (per JAPFA concern profile) - **UU 24/2009 Bahasa Indonesia bilingual missing:** INFO-only for outbound contracts. JAPFA is the principal; Levant cannot invoke UU 24/2009 against JAPFA in a Syrian court. No action needed for renewal unless JAPFA explicitly wants the defensive shield. - **Generic sanctions reps missing:** Mentioned as Risk #3 because Syria IS a Tier-1 overlay country. A sanctions exit clause is the correct remedy, not a generic compliance rep. #### Mandatory clauses confirmed present - Indonesian governing law (Art. 34.1) - Sub-distribution requires Supplier written consent (Art. 5.1) - MA bailee construction (Art. 4.2) - Tax gross-up (Art. 9.5) - Trademark non-transferable (Art. 10.1) - Confidentiality 5-year survival (Art. 16.5) - Force Majeure notice requirement (7 business days) - Inspection right (Art. 27) - Sales reports — monthly inventory, quarterly sales/registrations/tenders/financials (Art. 39) - Entire-agreement clause (Art. 30) - Severability (Art. 32) #### Mandatory clauses missing (real risks only) - KUHPerdata Art. 1266/1267 waiver - CISG exclusion - Sanctions exit + UBO warranty - Commercial-agency-law disclaimer (Syrian Law 12/2010) - Arabic translation requirement for Syrian state-court enforcement - Beirut-to-Damascus transit risk / title-transfer clause ### Tax & Stamp Duty - **Indonesian stamp duty (UU 10/2020):** Not visible on the PDF copies reviewed (evidentiary issue only — does not affect validity). - **Syrian stamp duty:** Verify with Syrian counsel post-transition. - **Withholding tax on cross-border payments:** Indonesia-Syria DTAA — none currently in force (verify). Payment structure (Levant pays USD pre-shipment to PT Vaksindo) means JAPFA receives gross USD; Syrian-side withholding would apply on Levant's outbound wire, mitigated by Art. 9.5 gross-up. - **VAT / GST treatment:** Not material under pre-shipment cash structure. - **Foreign Contractor Tax:** Not applicable (no service component). ### Sanctions / Anti-Bribery Exposure (INFO-context for tier-1 country) - **Live SDN exposure at review time (May 2026):** **No** — JAPFA compliance has cleared Levant Animal Health, its officers, and its payment bank. Verify monthly screening file is current. - **New SDN designation post-signing:** **No known** as of May 2026. - **Tier-1 sanctions overlay country:** **Yes** (Syria). Compliance section above flags Risk #3 (sanctions exit clause) as Critical because tier-1 status combined with absence of contractual exit creates real ongoing exposure even if no live SDN issue exists today. - **Sanctions screening clause in contract:** **Missing** — Risk #3 above. - **FCPA / UK Bribery Act reps:** **Minimal** (Art. 25.1 has generic anti-bribery wording, no FCPA/UKBA reference, no audit rights tied to anti-bribery). **Medium concern** — Syrian veterinary procurement often involves Syrian Ministry of Agriculture/Directorate of Veterinary Medicine (state entities); FCPA exposure is real if Levant pays unofficial fees to facilitate registration. **Recommendation:** Add explicit FCPA + UKBA reps + audit right at renewal. --- ## Obligations Timeline ### One-time deadlines (chronological) | Date / Trigger | Obligation | Owner | Clause | Consequence of miss | |----------------|------------|-------|--------|---------------------| | Effective Date (1 Apr 2024) + 15 days | Distributor provides label / packaging specifications | Distributor | 17.6 | Material breach (Art. 19.7) | | Receipt of full Dossier from Supplier + 18 months | Distributor obtains Syrian DOAH registration | Distributor | 4.2 | Supplier may terminate on 30 days' written notice | | Date of Syrian registration + 15 days | Distributor submits first Confirmed Purchase Order | Distributor | 17.12 | Supplier may withdraw registration + terminate | | First Product arrival + 15 days | Distributor launches Products in Syria | Distributor | 17.12 | Supplier may withdraw registration + terminate | ### Recurring obligations | Frequency | Obligation | Owner | Clause | Consequence of miss | |-----------|------------|-------|--------|---------------------| | Each PO (Live vaccines) | 60 business days lead time before estimated delivery | Distributor | 8.1 | Supplier need not accept short-lead orders | | Each PO (Killed vaccines) | 90 business days lead time | Distributor | 8.1 | Supplier need not accept short-lead orders | | Within 7 days of pro-forma invoice | Pre-shipment USD cash payment | Distributor | 9.1 | Supplier may decline to ship; non-payment is material breach | | Within 5 working days of pro-forma | Notify discrepancy | Distributor | 9.2 | Pro-forma deemed accepted | | Within 10 calendar days of receipt | Visual inspection report on shipment | Distributor | 13.2 | Quantity/quality claim deemed waived | | Monthly | Inventory report | Distributor | 39(a) | None specified (FLAG) | | Quarterly | Sales report | Distributor | 39(b) | None specified (FLAG) | | Quarterly | Status report on pending and approved Product registrations | Distributor | 39(c) | None specified (FLAG) | | Quarterly | Tender awards + Product developments + market data | Distributor | 39(d) | None specified (FLAG) | | Quarterly / Annually | Financial statements | Distributor | 39(e) | None specified (FLAG) | | Every 3 months | Rolling Projection Schedule (12-month annual sales forecast) | Distributor | 18.2 | None specified (FLAG) | | Annually before 31 October | Confirm next year's sales volumes | Both | 18.3 | If no agreement, **Supplier may appoint Third Party as distributor** — operational kill-switch | | Every 90 days | Progress report on registration applications | Distributor | 4.4 | None specified (FLAG) | | Sanctions screening (recommended) | Annual OFAC/EU/UN screening of Levant + officers + banks | JAPFA Compliance | — | Side-letter on sanctions exit needed | ### Year-tiered commercial commitments (Schedule A) | Year | Minimum purchase (units, all SKUs) | Sales Value (USD) | Discount tier | Clause | |------|--------------------------------------|-------------------|---------------|--------| | Year 1 (1 Apr 2024 – 31 Mar 2025) | 92,000 doses | **235,500** | None | Schedule A | | Year 2 (1 Apr 2025 – 31 Mar 2026) | 101,200 doses (+10%) | **259,050** | None | Schedule A | | Year 3 (1 Apr 2026 – 31 Mar 2027) | 111,320 doses (+10%) | **284,955** | None | Schedule A | **By SKU pricing (CIF USD per 1000 doses)** — for reference: Vaksimune IB NV1 $3.70 · Vaksimune IB QX $3.70 · Vaksimune IBD D/L $2.30 · Vaksimune IBH Duo $26.00 · Vaksimune ILT $3.50 · Vaksimune ND Clone $1.20 · Vaksimune ND Clone IB $2.20 · Vaksimune NDL Multi Inaktif $12.00 · Vaksimune ND LS $0.80 · Vaksimune ND LS IB $1.60 · Vaksimune NDL Multi IBPlus $27.00 · Vaksimune Pox $3.50. ### Trigger-based obligations | Trigger | Obligation | Window | Owner | Clause | Consequence of miss | |---------|------------|--------|-------|--------|---------------------| | Product complaint or AE received | Notify Supplier | 10 calendar days (BELOW MARKET — fix in renewal) | Distributor | 13.6 | Material breach | | Distributor ownership change / M&A | Written notice to Supplier | Pre-change | Distributor | 17.8 | Supplier may terminate on 30 business days' notice (Art. 23.2.c) | | Supplier-decided recall | Distributor coordinates recall in Territory | "Reasonable steps" | Distributor | 14.1-14.2 | Indemnity to Supplier for losses | | Government-required recall | Comply with notice + investigate cost allocation | Per government timing | Both | 15 | Cost on responsible Party | | Material breach by either Party | Cure | 60 calendar days from written notice | Breaching party | 23.2.e | Aggrieved party may terminate forthwith | | Insolvency / liquidation of either Party | Aggrieved party may terminate forthwith | Immediate | Aggrieved | 23.2.f | — | | Force Majeure | Notice to other Party | 7 Business Days | Affected | 28 | FM "deemed not to exist" | | FM persists | Either Party may terminate | 30 Business Days | Either | 28 | — | | Termination | Distributor sells off existing inventory | 6 months from termination | Distributor | 24.2 | — | | Termination | Distributor destroys / transfers all marketing materials | "Promptly" | Distributor | 24.3 | — | | Termination | Distributor files application to withdraw as marketing representative + cooperate inserting new representative | 30 days from Supplier request | Distributor | 24.5 | Supplier may carry out changes at Distributor's cost | | Sub-distribution proposed | Distributor requests Supplier written consent | Pre-action | Distributor | 5.1 | Breach if proceeds without consent | | Tender bid in Syria | Distributor furnishes Supplier confirmed PO upon receipt of tender doc + obtains Supplier written approval of tender price | Pre-bid | Distributor | 3.3, 8.2 | Material breach | ### Termination timeline | Step | Window | Notes | |------|--------|-------| | Notice for non-renewal at term end | **Not specified in contract** — Art. 23.1 says "the Parties may decide" to renew, otherwise terminates automatically. **FLAG: send formal non-renewal notice 90 days before 1 April 2027 to avoid ambiguity** (i.e., by **1 January 2027**). | | Cure period (material breach) | 60 days | Generous to Distributor (market is 30 days); not a deal-killer | | Run-off period post-termination | 6 months | Standard | | Stock buy-back | None automatic | Supplier has discretionary right to "reacquire" Products (Art. 24.2) — no price formula specified (FLAG) | | MA / NIE transfer to JAPFA nominee | 30 days from Supplier request | Aggressive timeline given Syrian DOAH practical 6-12 months. **Plan transfer-back orchestration to start before contract end.** | | Confidentiality survival | 5 years post-termination | Standard | | Sanctions exit (recommended via side-letter) | Immediate | Not currently in contract — see Risk #3 | ### Regulatory cliff dates | Item | Date / cycle | Owner | Risk | |------|--------------|-------|------| | Syrian DOAH product registration | Per-product, 6-12 months post-Dossier submission (post-transition) | Distributor | Loss of market access; 18-month outside-deadline triggers Supplier termination right | | LOA expiry | **1 April 2027** (mirrors agreement term) | JAPFA | Re-issue at renewal; counterparty has NOT countersigned current LOA (unilateral grant) | ### Operational alerts - **Notice consequences NOT specified** for monthly inventory report, quarterly sales report, quarterly registration status report, quarterly tender awards report, quarterly/annual financials, 90-day registration progress report, rolling forecast — **counterparty can stall reporting with no contract consequence**. (FLAG) - **Year-tiered minimum purchase floors not tied to a discount tier** — JAPFA misses opportunity to incentivize over-performance. - **Stock buy-back price formula missing** — Art. 24.2 grants Supplier "right to reacquire" but does not specify price (COGS? Net? Distributor's invoice?). At termination this is a litigation hotspot. - **31 October annual minimum-reset deadline is a key cliff date** — if Parties fail to agree on Year N+1 volumes before 31 October of Year N, Supplier can appoint a third party (Art. 18.3). **Both sides should diary 1 October every year to start the discussion.** - **18-month "no registration" termination trigger** (Art. 4.2): the Dossier was provided 1 April 2024; if registration was not obtained by **1 October 2025**, Supplier has a right to terminate on 30 days' notice. **Action: confirm with JAPFA International Business whether Levant has obtained Syrian DOAH registration for any/all SKUs in Schedule A by today's date. If not, JAPFA has an unused leverage point.** - **Sub-distribution to local Syrian distributors:** Art. 12.1 anticipates Levant using "their own / local distributor's distribution network." Combined with the Art. 5.1 written-consent requirement, JAPFA should ensure every Syrian sub-distributor is named in writing. --- ## Internal Consistency Findings | Issue | Severity | Location | Detail | |---|---|---|---| | Self-contradictory exclusivity language | Material | Art. 2.1 | "non exclusive… exclusively in the Territory" in the same sentence | | Section 5 heading vs operative provisions | Material | Art. 5 | Section titled "Non-Exclusivity" but the operative clauses (5.1, 5.2) only restrict the Distributor — no JAPFA-side non-exclusivity language | | Art. 23.2 sub-clause lettering jumps (a, b, c, **e**, f) | Minor | Art. 23.2 | Sub-clause (d) is missing — likely drafting error in editing from a master | | Both signature dates blank | Minor | Pages 16 + 17 | Effective Date 1 April 2024 per recital is fixed, but no execution dates on either signature | | LOA terminates 1 April 2027 but only Vaksindo has signed | Minor | LOA in Draft folder | Levant has not countersigned LOA; unilateral instrument | | Contract Article 28 (FM termination right) and Article 23.2 (other termination grounds) do not cross-reference | Minor | Art. 28 + 23.2 | Two parallel termination triggers — workable but inelegant | | Schedule A volumes given only for 3 years (Years 1-3) | Acceptable | Schedule A | Matches 3-year term — but expanded escalation clauses (10%) should be tested at renewal | ### Priority Focus Area Coverage 1. **Territory:** Covered Art. 1.13 (Syria). Status: OK. 2. **Exclusivity:** Covered Art. 2.1 + Art. 5. Status: **CRITICAL — internally contradictory; see Risk #5.** 3. **Pricing:** Covered Art. 3 + Schedule A. Status: OK; pre-shipment USD cash (strongest in portfolio). 4. **Termination:** Covered Art. 23 + Art. 24. Status: **Risk noted — KUHPerdata 1266/1267 waiver missing (Risk #6); Syrian Law 12/2010 exposure (Risk #4).** 5. **Sales targets:** Covered Art. 7 + Schedule A. Status: OK with take-or-pay; 10% annual escalator. 6. **Registration / MA ownership** (including practical recoverability): Covered Art. 4. Status: **OK on paper** (bailee construction); **practical recoverability for Syria 6-12 months minimum due to chaotic post-Assad-transition DOAH.** 7. **Time-tiered discounts:** Status: **No mechanism — gap (info).** 8. **International dispute / governing law** (including enforceability in counterparty country): Covered Art. 34. Status: **CRITICAL — hybrid forum defect (Risk #1).** 9. **Multi-distributor permissibility**: Status: **CONDITIONAL (leaning NO without cost). Ambiguous Art. 2.1 + Syrian Law 12/2010 stickiness. See Compliance Q3.** 10. **Counterparty-country voidance risks (Syria)**: Status: **Multiple gaps — no Arabic translation acknowledgement, no commercial-registry filing acknowledgement, no FX repatriation acknowledgement, no sanctions exit clause, no FCPA reps. See Compliance Q4 + Risks #3 and #4.** --- ## Action Items (Numbered for diary) ### Day 0 (this week) 1. **Diary: send formal non-renewal/renewal-decision notice by 1 January 2027** (90 days before term end 1 April 2027). Owner: JAPFA Legal + Yusman Friyadi (per Art. 37 notice clause). 2. **Confirm with JAPFA International Business: has Levant obtained Syrian DOAH registration for each SKU?** If 18 months from Dossier delivery has expired without registration, JAPFA holds an unused termination right (Art. 4.2 last sentence). Owner: JAPFA International Business + Yusman Friyadi. 3. **Compile current OFAC/EU/UN screening file for Levant Animal Health + Dr. Mona Abd Al Malek + Levant's payment bank.** Date it. Owner: JAPFA Compliance. ### Day 7-30 4. **Draft and send a 3-item side-letter** to Levant Animal Health containing: (a) Election of SIAC Singapore + English + 3 arbitrators as sole forum (Risk #1 clause text) (b) Sanctions exit clause (Risk #3 clause text) (c) KUHPerdata Art. 1266/1267 waiver + CISG exclusion (Risk #6 clause text) Owner: JAPFA Legal. Cite: portfolio-wide template fix (do not present as a renegotiation). 5. **Send a written inquiry to Levant** asking whether Levant has registered (i) the Distribution Agreement or (ii) itself as a commercial agent with the Syrian Ministry of Industry or any other Syrian authority. Document the answer. (Risk #4) Owner: JAPFA Legal. 6. **Engage Syrian local counsel** for a 1-page memo on post-Assad-transition (a) enforcement of foreign arbitral awards, (b) Commercial Agencies Law 12/2010 current case practice, (c) commercial registry filing process for distribution agreements, (d) Hague apostille / consular legalization current practice. Cost expectation: USD 1.5K-3K. Owner: JAPFA Legal. ### Day 30-90 (Q3 2026) 7. **Re-issue the LOA bilaterally** — current LOA in Draft folder is Vaksindo-only; have Levant countersign for executive completeness. Owner: Yusman Friyadi. 8. **Begin renewal-planning workstream**: revised contract template with the 8 issues fixed (Risks #1-#8). Distribute internally for comment. Owner: JAPFA Legal. 9. **Diary every 1 October** for the annual minimum-purchase confirmation deadline (Art. 18.3) — both sides must agree by 31 October on next year's volumes, or JAPFA may appoint a third party. ### Day 90-365 (Q4 2026 – April 2027) 10. **Schedule renewal-planning meeting with Levant for September 2026** — open the door to a 5-year successor agreement with the template fixes baked in (matches Syrian Law 12/2010 5-year expectation; clean clauses; expanded Schedule A). 11. **If non-renewal decided**: start MA transfer-back orchestration **6 months before term end** (October 2026). Syrian DOAH practical timeline is 6-12 months. Owner: JAPFA International Business + JAPFA Veterinary. --- ## Appendix A — Draft Side-letter Clauses ### Sanctions Exit (for side-letter) > *"Sanctions Exit. JAPFA may terminate this Agreement immediately upon written notice if (a) Distributor or any of its directors, officers, ultimate beneficial owners, or contractually-engaged banks becomes a Sanctioned Person, or is owned 50% or more by a Sanctioned Person; or (b) the performance of this Agreement would cause JAPFA to violate any applicable sanctions regime administered by the US Office of Foreign Assets Control, the European Union, the United Nations Security Council, or the United Kingdom. 'Sanctioned Person' means any person or entity (i) listed on OFAC's Specially Designated Nationals and Blocked Persons List, the EU consolidated sanctions list, or the UN Security Council sanctions list, or (ii) the government, agency or instrumentality of, or organized under the laws of, any country subject to comprehensive sanctions. Distributor warrants that as of the date of this side-letter and on each shipment date, Distributor and its UBOs are not Sanctioned Persons."* ### Dispute Resolution (replaces Article 34.2) > *"Any dispute, controversy or claim arising out of or relating to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof, shall be referred to and finally resolved by arbitration administered by the Singapore International Arbitration Centre ('SIAC') in accordance with the Arbitration Rules of SIAC for the time being in force, which rules are deemed to be incorporated by reference in this clause. The seat of arbitration shall be Singapore. The Tribunal shall consist of three (3) arbitrators. The language of the arbitration shall be English. The 1980 United Nations Convention on Contracts for the International Sale of Goods is expressly excluded. The Parties expressly waive Articles 1266 and 1267 of the Indonesian Civil Code (KUHPerdata) such that no court order shall be required to effect termination of this Agreement in accordance with its terms. Either Party may seek interim or injunctive relief from any court of competent jurisdiction without waiving the agreement to arbitrate."* ### Syrian Commercial-Agency-Law Disclaimer (renewal) > *"The Parties agree that Distributor is appointed as an independent distributor purchasing and reselling on its own account, NOT as a commercial agent. Distributor warrants that it has not registered, and will not register, this Agreement or itself as a commercial agent of Supplier with the Syrian Ministry of Industry or any other Syrian governmental authority without Supplier's prior written consent. The Parties expressly disclaim the application of Syrian Commercial Agencies Law No. 12 of 2010 to this Agreement to the maximum extent permitted by Syrian law. Any termination of this Agreement in accordance with its terms shall give rise to no indemnity, compensation, or goodwill payment from Supplier to Distributor."* ### Force Majeure (renewal) > *"For purposes of this Agreement, 'Force Majeure' means an event beyond the reasonable control of the affected Party that could not have been prevented by the exercise of reasonable diligence, limited to: (a) acts of God (earthquake, fire, flood, storm); (b) war, armed conflict, terrorism, or insurrection; (c) genuine epidemic or pandemic declared by the World Health Organization; (d) government export ban or sanction directly preventing performance by the supplier-side Party. For avoidance of doubt, Force Majeure does NOT include: (i) labor disputes affecting the affected Party's own workforce; (ii) raw-material shortages; (iii) currency fluctuations or foreign-exchange controls; (iv) regulatory delay foreseeable as of the Effective Date; (v) economic hardship. The Party invoking Force Majeure shall give written notice within seven (7) Business Days. If Force Majeure persists more than ninety (90) Business Days, either Party may terminate."* ### Liability Cap (renewal) > *"Each Party's aggregate liability arising out of or relating to this Agreement shall not exceed twelve (12) months of Net Sales calculated as the aggregate purchase price paid by Distributor under this Agreement in the twelve (12) months preceding the event giving rise to the claim. The foregoing cap shall not apply to: (a) death or personal injury; (b) fraud; (c) willful misconduct; (d) breach of confidentiality; (e) intellectual property infringement; (f) product recall costs arising from willful misconduct or gross negligence; (g) anti-bribery or sanctions breach; (h) breach of payment obligations; or (i) any liability that cannot lawfully be limited under Indonesian law."* ### Adverse Event Reporting (renewal) > *"Distributor shall report to Supplier (a) Serious Adverse Events (death, life-threatening condition, persistent disability, congenital anomaly, or other clinically significant outcome) within twenty-four (24) hours of becoming aware; and (b) Non-Serious Adverse Events and all Quality Complaints within five (5) Business Days. Reports shall be sent in writing to pharmacovigilance@japfa.com with copy to Supplier's Quality Assurance head. Distributor shall preserve all original complaint documentation for not less than ten (10) years."* --- ## Appendix B — LOA Extract (Letter of Authorization Syria) **Path:** `004 Agreement Masterfile/Syria - Levant Animal Health/Draft/Letter of Authorization Syria.docx` **Note:** The LOA is filed under the "Draft" subfolder, not "Signed." Only Dr. Teguh Yodiantara Prajitno's signature block is present; Levant Animal Health has not countersigned. The LOA functions as a unilateral grant from PT Vaksindo Satwa Nusantara — sufficient for filing with Syrian DOAH on Levant's behalf, but does not record bilateral consent. **Action: countersign for completeness at next opportunity.** **Validity:** Until **1 April 2027** (matches agreement term). **Authorized counterparty:** Al Haytham for Trade Limited Liability — Levant Animal Health (C.R. no. 17433, Damascus countryside, Syria). **Authority granted:** To register, import, distribute, and sell PT Vaksindo Satwa Nusantara products in Syria via the Syrian DOAH (Directorate of Animal Health), Ministry of Agriculture. **Products authorized (17 SKUs):** | # | Product | Cross-reference to Schedule A? | |---|---------|--------------------------------| | 1 | VAKSIMUNE NDLS | ✓ Schedule A | | 2 | VAKSIMUNE NDLS IB | ✓ Schedule A | | 3 | VAKSIMUNE ND CLONE | ✓ Schedule A | | 4 | VAKSIMUNE ND CLONE IB | ✓ Schedule A | | 5 | VAKSIMUNE IBD L | ✓ Schedule A | | 6 | VAKSIMUNE IBD D | ✓ Schedule A | | 7 | VAKSIMUNE IBD M+ | NOT in Schedule A | | 8 | VAKSIMUNE IB QX | ✓ Schedule A | | 9 | VAKSIMUNE IB NV-1 | ✓ Schedule A (as "Vaksimune IB NV1") | | 10 | VAKSIMUNE POX | ✓ Schedule A | | 11 | VAKSIMUNE ILT | ✓ Schedule A | | 12 | VAKSIMUNE ND INAKTIF | NOT in Schedule A | | 13 | VAKSIMUNE NDL MULTI INAKTIF | ✓ Schedule A | | 14 | VAKSIMUNE NDL MULTI IBPLUS EDS | NOT in Schedule A | | 15 | VAKSIMUNE NDL INAKTIF 0,1 | NOT in Schedule A | | 16 | VAKSIMUNE IBH DUO | ✓ Schedule A (as "Vaksimune IBH Duo") | | 17 | VAKSIMUNE NDL MULTI IBPLUS | ✓ Schedule A (as "Vaksimune NDL Multi IBPlus") | **Authorization vs Schedule A gap:** 4 SKUs are authorized in the LOA but not in Schedule A (IBD M+, ND Inaktif, NDL Multi IBPlus EDS, NDL Inaktif 0.1). These products may be sold under the LOA's regulatory authorization (so JAPFA can register them in Syrian DOAH) but are NOT subject to the agreement's take-or-pay minimum purchase. If JAPFA wants to monetize these SKUs in Syria, **add them to Schedule A at renewal** with their own minimum-purchase obligations. --- ## LOA JSON Structure (for state file) ```json "loa_current": { "file": "Syria - Levant Animal Health/Draft/Letter of Authorization Syria.docx", "folder_subdirectory": "Draft", "note": "Filed under 'Draft' not 'Signed'; functions as unilateral grant by Vaksindo only — counterparty has not countersigned. Re-sign bilaterally at next opportunity.", "effective_date": null, "signing_date": null, "validity_end_date": "2027-04-01", "matches_agreement_term": true, "signatory_japfa": "Dr. Teguh Yodiantara Prajitno (President Director, PT Vaksindo Satwa Nusantara)", "signatory_distributor": null, "distributor_legal_name": "Al Haytham for Trade Limited Liability Company", "distributor_trade_name": "Levant Animal Health", "distributor_commercial_register": "C.R. no. 17433", "distributor_address": "Damascus countryside, Syria", "territory": "Syria", "authority_granted": "Register, import, distribute, sell to Syrian DOAH (Directorate of Animal Health), Ministry of Agriculture", "products": [ {"name": "Vaksimune NDLS", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 20000, "annual_volume_authorized_y2": 22000, "annual_volume_authorized_y3": 24200}, {"name": "Vaksimune NDLS IB", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 10000, "annual_volume_authorized_y2": 11000, "annual_volume_authorized_y3": 12100}, {"name": "Vaksimune ND Clone", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 20000, "annual_volume_authorized_y2": 22000, "annual_volume_authorized_y3": 24200}, {"name": "Vaksimune ND Clone IB", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 10000, "annual_volume_authorized_y2": 11000, "annual_volume_authorized_y3": 12100}, {"name": "Vaksimune IBD L", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 5000, "annual_volume_authorized_y2": 5500, "annual_volume_authorized_y3": 6050}, {"name": "Vaksimune IBD D", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 5000, "annual_volume_authorized_y2": 5500, "annual_volume_authorized_y3": 6050}, {"name": "Vaksimune IBD M+", "in_schedule_a": false, "dose_sku": null, "annual_volume_authorized_y1": null, "annual_volume_authorized_y2": null, "annual_volume_authorized_y3": null, "note": "Authorized in LOA, NOT included in Schedule A minimums"}, {"name": "Vaksimune IB QX", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 5000, "annual_volume_authorized_y2": 5500, "annual_volume_authorized_y3": 6050}, {"name": "Vaksimune IB NV-1", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 10000, "annual_volume_authorized_y2": 11000, "annual_volume_authorized_y3": 12100}, {"name": "Vaksimune Pox", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 2000, "annual_volume_authorized_y2": 2200, "annual_volume_authorized_y3": 2420}, {"name": "Vaksimune ILT", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 2000, "annual_volume_authorized_y2": 2200, "annual_volume_authorized_y3": 2420}, {"name": "Vaksimune ND Inaktif", "in_schedule_a": false, "dose_sku": null, "annual_volume_authorized_y1": null, "annual_volume_authorized_y2": null, "annual_volume_authorized_y3": null, "note": "Authorized in LOA, NOT included in Schedule A minimums"}, {"name": "Vaksimune NDL Multi Inaktif", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 1000, "annual_volume_authorized_y2": 1100, "annual_volume_authorized_y3": 1210}, {"name": "Vaksimune NDL Multi IBPlus EDS", "in_schedule_a": false, "dose_sku": null, "annual_volume_authorized_y1": null, "annual_volume_authorized_y2": null, "annual_volume_authorized_y3": null, "note": "Authorized in LOA, NOT included in Schedule A minimums"}, {"name": "Vaksimune NDL Inaktif 0.1", "in_schedule_a": false, "dose_sku": null, "annual_volume_authorized_y1": null, "annual_volume_authorized_y2": null, "annual_volume_authorized_y3": null, "note": "Authorized in LOA, NOT included in Schedule A minimums"}, {"name": "Vaksimune IBH Duo", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 1000, "annual_volume_authorized_y2": 1100, "annual_volume_authorized_y3": 1210}, {"name": "Vaksimune NDL Multi IBPlus", "in_schedule_a": true, "dose_sku": "1000ds", "annual_volume_authorized_y1": 1000, "annual_volume_authorized_y2": 1100, "annual_volume_authorized_y3": 1210} ], "loa_text_path": "output/lawyer-advisor/working/2026-05-13-syria-levant-loa.txt" }, "loa_history": [] ``` --- ## File Paths Referenced - **Signed agreement (text-PDF):** `C:\Users\NEXBIT Z14\OneDrive - JAPFA\Documents - International Business\004 Agreement Masterfile\Syria - Levant Animal Health\Signed\05.04.2024 Distribution Agreement Levant Animal Health.pdf` - **Signed agreement (scanned counterpart, same legal entity):** `C:\Users\NEXBIT Z14\OneDrive - JAPFA\Documents - International Business\004 Agreement Masterfile\Syria - Levant Animal Health\Signed\Signed Distribution Agreement AL HAYTHAM - Syria.pdf` - **Letter of Authorization:** `C:\Users\NEXBIT Z14\OneDrive - JAPFA\Documents - International Business\004 Agreement Masterfile\Syria - Levant Animal Health\Draft\Letter of Authorization Syria.docx` - **Extracted text:** `C:\Users\NEXBIT Z14\OneDrive\Claude\output\lawyer-advisor\working\2026-05-13-syria-levant-agreement.txt` - **Extracted LOA text:** `C:\Users\NEXBIT Z14\OneDrive\Claude\output\lawyer-advisor\working\2026-05-13-syria-levant-loa.txt` - **This memo:** `C:\Users\NEXBIT Z14\OneDrive\Claude\output\lawyer-advisor\2026-05-13-syria-levant-review.md` --- *End of review. Advisory analysis only. Verify with Syrian local counsel before relying on any post-Assad-transition enforcement assumption.*